Abivax SA - Asset Resilience Ratio

Latest as of March 2025: 46.27%

Abivax SA (ABVX) has an Asset Resilience Ratio of 46.27% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Abivax SA debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€77.24 Million

≈ $90.30 Million USD Cash + Short-term Investments

Total Assets

€166.94 Million

≈ $195.17 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how Abivax SA's Asset Resilience Ratio has changed over time. See ABVX book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Abivax SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abivax SA market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€69.71 Million	41.76%
Short-term Investments	€7.53 Million	4.51%
Total Liquid Assets	€77.24 Million	46.27%

Asset Resilience Insights

Very High Liquidity: Abivax SA maintains exceptional liquid asset reserves at 46.27% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Abivax SA Industry Peers by Asset Resilience Ratio

Compare Abivax SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Abivax SA (2013–2024)

The table below shows the annual Asset Resilience Ratio data for Abivax SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	42.59%	€87.40 Million ≈ $102.18 Million	€205.23 Million ≈ $239.93 Million	+34.28pp
2023-12-31	8.30%	€27.16 Million ≈ $31.75 Million	€327.06 Million ≈ $382.37 Million	+8.29pp
2022-12-31	0.02%	€12.00K ≈ $14.03K	€73.35 Million ≈ $85.76 Million	+0.01pp
2021-12-31	0.01%	€12.00K ≈ $14.03K	€110.36 Million ≈ $129.03 Million	-0.01pp
2020-12-31	0.02%	€12.00K ≈ $14.03K	€71.30 Million ≈ $83.35 Million	-0.01pp
2019-12-31	0.02%	€12.00K ≈ $14.03K	€51.73 Million ≈ $60.48 Million	-18.50pp
2018-12-31	18.52%	€10.01 Million ≈ $11.71 Million	€54.05 Million ≈ $63.19 Million	-37.78pp
2017-12-31	56.31%	€30.30 Million ≈ $35.43 Million	€53.81 Million ≈ $62.92 Million	+6.64pp
2016-12-31	49.67%	€30.10 Million ≈ $35.19 Million	€60.60 Million ≈ $70.84 Million	-1.47pp
2015-12-31	51.15%	€39.01 Million ≈ $45.60 Million	€76.27 Million ≈ $89.17 Million	+46.66pp
2014-12-31	4.49%	€1.70 Million ≈ $1.99 Million	€37.97 Million ≈ $44.39 Million	+3.45pp
2013-12-31	1.04%	€400.00K ≈ $467.64K	€38.46 Million ≈ $44.97 Million	--

pp = percentage points

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$8.78 Billion

€7.51 Billion EUR

Market Cap Rank

#2866 Global

#55 in France

Share Price

€96.45

Change (1 day)

+3.16%

52-Week Range

€5.06 - €122.40

All Time High

€122.40